Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes
The Journal of Immunology · 15.04.2026 · 215 (4)
DOI: 10.1093/jimmun/vkag056 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 17.04.2026. Verfasst von Rafid Al-Hallaf und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoantibodies, Immunoglobulin M, CD8-Positive T-Lymphocytes. Die Arbeit nennt 58 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Current immunotherapies for autoimmune diseases lack sufficient specificity and often compromise protective immunity, underscoring the need for precision-based approaches. Here, we identify x-mAb, a germline-encoded IgM autoantibody derived from dual-expresser lymphocytes of patients with type 1 diabetes (T1D), as a potent agent for precision immunotherapy. In the nonobese diabetic mouse model, x-mAb prevents disease onset, induces durable remission, and preserves functional pancreatic islets without disrupting systemic immune homeostasis. Mechanistically, x-mAb selectively targets islet-reactive CD4 and CD8 tissue-resident memory (Trm) T cells in pancreas and pancreatic lymph nodes, as shown by MHC tetramer staining and in vivo tracking. x-mAb engagement downregulates CD69, a key Trm retention molecule, resulting in a marked reduction of pathogenic pancreatic T cells. Critically, x-mAb recognizes analogous CD69+ Trm-like peripheral T cells in T1D patients and downregulates CD69 ex vivo, indicating a conserved and therapeutically targetable mechanism across species. Structural modeling revealed that x-mAb engages TCRαβ through multiple contact sites, with the most stable interactions targeting a conserved CDR3α SGGGGS motif shared by diabetogenic human and mouse clonotypes. Based on these findings, we propose natural IgM autoantibodies as a previously unrecognized reservoir for precision biologics that selectively target autoreactive T cells while preserving immune competence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Institute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou, China.
- Computational Biology Center, IBM Thomas J. Watson Research Center, Yorktown Heights, NY, United States.
- Department of Chemistry, Columbia University, New York, NY, United States.
- Department of Biochemistry and Nutrition, Des Moines University, Des Moines, IA, United States.
ORCID-Profile: Patrizio Caturegli
Zitieren
APA
Al-Hallaf, R., Agha, Z., Caturegli, P., Rosenberg, A., Wolf, R., Chan, K. C., Song, Y., Lee, S., Zhou, R., Jie, C., Donner, T., & Hamad, A. R. A. (2026). Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes. The Journal of Immunology, 215(4). https://doi.org/10.1093/jimmun/vkag056
Vancouver
Al-Hallaf R, Agha Z, Caturegli P, Rosenberg A, Wolf R, Chan KC, et al. Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes. The Journal of Immunology. 2026;215(4). doi:10.1093/jimmun/vkag056
BibTeX
@article{AlHallaf2026,
author = {Al-Hallaf, Rafid and Agha, Zainab and Caturegli, Patrizio and Rosenberg, Avi and Wolf, Risa and Chan, Kevin C and Song, Yi and Lee, Sangyun and Zhou, Ruhong and Jie, Chunfa and Donner, Thomas and Hamad, Abdel Rahim A},
title = {Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {4},
doi = {10.1093/jimmun/vkag056}
}
EUVIMED